» Articles » PMID: 22234810

A Comparison of Case-finding Strategies in the UK for the Management of Hip Fractures

Overview
Journal Osteoporos Int
Date 2012 Jan 12
PMID 22234810
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Treatment criteria published by the National Osteoporosis Guideline Group (NOGG) in the UK make more efficient use of bone mineral density (BMD) resources than the previous Royal College of Physicians (RCP) guideline.

Introduction: We compared the effectiveness of the RCP case-finding strategy previously used in the UK and the updated guideline published by NOGG, which incorporates the FRAX® fracture probability tool.

Methods: Comparisons were made by simulating population samples of 1000 women at ages between 50 and 85 years, using age-specific prevalence of risk factors and UK-derived fracture and mortality rates. Comparators comprised the number identified at high risk, the incidence of hip fracture and the femoral neck BMD in those identified, the number needed to scan to identify a hip fracture, the acquisition cost and the cost per hip fracture averted

Results: Compared with the RCP strategy, NOGG identified slightly reduced numbers of women at high risk (average 34.6% vs. 35.7% across all ages), but with lower numbers of scans required at each age. For example, NOGG required only 3.5 scans at the age of 50 years to identify one case of hip fracture, whereas RCP required 13.9. At 75 years, the corresponding numbers were 0.9 and 1.5. Thus, the acquisition costs for identifying a hip fracture case and the total costs (acquisition and treatment) per hip fracture averted were lower.

Conclusion: Compared to the RCP strategy, the FRAX-based NOGG strategy uses BMD resources more efficiently with lower acquisition costs and lower costs per hip fracture averted.

Citing Articles

A surrogate FRAX model for Mongolia.

Jaalkhorol M, Johansson H, Avirmed S, Dashtseren A, Bruyere O, Lorentzon M Arch Osteoporos. 2025; 20(1):27.

PMID: 39955704 PMC: 11830636. DOI: 10.1007/s11657-025-01501-y.


FRAX-derived intervention and assessment thresholds for osteoporosis in ten Middle Eastern countries.

Naseri A, Bakhshayeshkaram M, Salehi S, Heydari S, Dabbaghmanesh M, Dabbaghmanesh M Arch Osteoporos. 2024; 19(1):41.

PMID: 38780743 DOI: 10.1007/s11657-024-01397-0.


An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.

Schini M, Johansson H, Harvey N, Lorentzon M, Kanis J, McCloskey E J Endocrinol Invest. 2023; 47(3):501-511.

PMID: 37874461 PMC: 10904566. DOI: 10.1007/s40618-023-02219-9.


An assessment of intervention thresholds for high fracture risk in Chile.

Lopez Gavilanez E, Luis I, Mario N, Johansson H, Harvey N, Lorentzon M Arch Osteoporos. 2022; 18(1):11.

PMID: 36527508 DOI: 10.1007/s11657-022-01198-3.


Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group.

Chotiyarnwong P, McCloskey E, Harvey N, Lorentzon M, Prieto-Alhambra D, Abrahamsen B Arch Osteoporos. 2022; 17(1):87.

PMID: 35763133 PMC: 9239944. DOI: 10.1007/s11657-022-01117-6.


References
1.
Johansson H, Kanis J, McCloskey E, Oden A, Devogelaer J, Kaufman J . A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int. 2010; 22(2):453-61. DOI: 10.1007/s00198-010-1218-1. View

2.
Compston J, Cooper A, Cooper C, Francis R, Kanis J, Marsh D . Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62(2):105-8. DOI: 10.1016/j.maturitas.2008.11.022. View

3.
Compston J . Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ. 2009; 338:b1276. DOI: 10.1136/bmj.b1276. View

4.
Watts N, Lewiecki E, Miller P, Baim S . National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008; 11(4):473-7. DOI: 10.1016/j.jocd.2008.04.003. View

5.
Black D, Schwartz A, Ensrud K, Cauley J, Levis S, Quandt S . Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296(24):2927-38. DOI: 10.1001/jama.296.24.2927. View